TG Therapeutics Surges as Briumvi Sales Drive Strong Multiple Sclerosis Growth
TG Therapeutics Surges as Briumvi Sales Drive Strong Multiple Sclerosis Growth
TG Therapeutics drew fresh attention from biotech investors after reporting a sharp rise in profit and revenue, supported by strong demand for its multiple sclerosis treatment, Briumvi.
The company said first-quarter earnings reached 12 cents per share, about four times higher than the same period a year earlier. Revenue rose 70% to $204.9 million, showing that Briumvi is becoming a bigger commercial force in the relapsing multiple sclerosis market.
Briumvi Becomes the Main Growth Engine
Briumvi, also known as ublituximab, is approved for adults with relapsing forms of multiple sclerosis. TG Therapeutics says the drug is cleared by the U.S. FDA for conditions including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It has also gained approvals outside the United States for certain adult RMS patients.
The treatment is given as a twice-yearly infusion, a dosing schedule that may appeal to patients and doctors looking for less frequent treatment visits. According to the report, more than 25,000 patients globally have used Briumvi, helping TG Therapeutics strengthen its position in the competitive MS drug market.
Company Raises Revenue Outlook
After the strong quarter, TG Therapeutics lifted its financial expectations. The company now expects around $220 million in Briumvi revenue for the second quarter and raised its full-year 2026 global revenue forecast to about $925 million.
This improved outlook suggests management sees continued demand for Briumvi through the year. It also signals confidence that the medicine can keep gaining traction despite competition from large pharmaceutical companies in the multiple sclerosis treatment space.
Pipeline Development Adds Investor Interest
Beyond the current infusion product, TG Therapeutics is working on a subcutaneous version of Briumvi, which is being studied in a Phase 3 trial. A successful easier-to-administer version could make the treatment more convenient and potentially expand its commercial reach.
The company is also exploring additional neurological and B-cell disease therapies, giving investors another reason to watch its long-term pipeline. However, biotech development remains uncertain, and trial results, regulatory reviews, pricing pressure, and competition can all affect future performance.
TGTX Stock Shows Strength
TGTX stock has also performed strongly, rising about 32% year-to-date according to the report. Investor’s Business Daily noted that the stock held an IBD Composite Rating of 88 and a B+ Accumulation/Distribution Rating, reflecting solid market and institutional interest.
Still, the stock’s technical setup carries some risk. The report noted that shares were forming a cup-with-handle pattern, but the handle’s pullback was somewhat deeper than preferred by IBD’s usual standards. That means investors may be optimistic, but they are also watching carefully for confirmation.
Competition Remains a Key Risk
The multiple sclerosis market is highly competitive. Briumvi competes with major treatments from larger companies, including Roche’s Ocrevus and other MS therapies. Recent Roche trial data for fenebrutinib also pressured TG Therapeutics shares in the past, showing how quickly new clinical results can affect biotech sentiment.
For TG Therapeutics, the main question is whether Briumvi can keep growing while defending its place against both established drugs and newer treatment options. Strong sales show momentum, but the company must continue proving that its therapy offers meaningful value for patients, doctors, and payers.
Why This Matters
TG Therapeutics’ latest results show a biotech company moving from promise to commercial execution. The jump in profit, rising revenue, and higher guidance all point to stronger business momentum. At the same time, investors should remember that biotech stocks can be volatile, especially when they depend heavily on one leading product.
Overall, TG Therapeutics is entering a more important stage. Briumvi’s growth is giving the company financial strength, while pipeline work may open new opportunities. If demand continues and clinical development stays on track, the company could remain one of the more closely watched names in the multiple sclerosis biotech sector.
#TGTX #TGTherapeutics #Briumvi #MultipleSclerosis #SlimScan #GrowthStocks #CANSLIM